[Abstract Only] Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer – New England Journal of Medicine (free)

Commentaries: SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer – The ASCO Post (free) AND HER2CLIMB and DESTINY-Breast01 Findings in Heavily Pretreated HER2-positive MBC – ESMO (free)